Skip to main navigation Skip to search Skip to main content

Advanced EGFR-mutant NCSLC resistant to osimertinib therapy as a result of a novel CGN-RET fusion mutation with favorable response to combined osimertinib and selpercaptinib, case report

    Research output: Contribution to journalArticlepeer-review

    Original languageEnglish
    Article number100246
    JournalCurrent Problems in Cancer: Case Reports
    Volume11
    DOIs
    StatePublished - Sep 2023

    ASJC Scopus Subject Areas

    • Oncology

    Keywords

    • Case report
    • EGFR-mutant
    • NSCLC
    • RET-mutant

    Cite this